Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Actelion delivers outstanding 2014 results

Jean-Paul Clozel, CEO: "2014 was an outstanding
year for Actelion, with successes on all fronts.
We’ve delivered strong sales growth and
saw a substantial uptake of the
recently launched Opsumit."

Jean-Paul Clozel, CEO: "2014 was an outstanding
year for Actelion, with successes on all fronts.
We’ve delivered strong sales growth and
saw a substantial uptake of the
recently launched Opsumit."

Global Actelion

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 12:03:26 CET 02/03/2015
CHF 114,40Up Down image
+0,30 (+0,26%)